Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
The GLOBE Model represents the most structurally aggressive drug pricing intervention CMS has attempted through the Innovation Center's Section 1115A authority. Its architecture is notable for what it doesn't do: it does not impose price controls on manufacturers directly. Instead, it deploys a rebate mechanism that functionally achieves the same result — pulling Medicare's net cost for targeted Part B drugs toward international benchmark levels — while preserving the statutory appearance of market pricing.
The model runs January 1, 2027 through March 31, 2032, with rebate invoicing and reconciliation extending into 2034. The coinsurance reduction window is narrower: April 1, 2027 through March 31, 2032.
The reference country list is a design signal, not a neutral technical choice. The 19 comparator countries — Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, and the United Kingdom — are a deliberate assembly of high-income nations with negotiated or reference-priced pharmaceutical markets. These countries' net prices average 40–70% below U.S. list prices for the drug classes targeted here.
Therapeutic class targeting reveals the financial logic. GLOBE focuses on oncology, rheumatology, immunology, ophthalmology, and endocrinology — the five highest-expenditure therapeutic areas in Part B — with the $100 million annual Original Medicare spending threshold as the eligibility filter.
Critical update — final rule narrows scope and savings: Recent reporting from multiple sources, including Endpoints News, ASCO, and Healthcare Finance News, confirms that the final rule is materially narrower in scope and projected savings than the proposed rule. ASCO specifically noted that the "scope and financial impact of the GLOBE Part B Drug Pricing Model [was] narrowed in the final rule." Endpoints News reported that "savings trail projections," and Healthcare Finance News headlined that the "final GLOBE drug model saves less money than originally proposed." The specific nature of the scope narrowing — whether driven by therapeutic class exclusions, threshold adjustments, or benchmark methodology changes — was not fully detailed in available article summaries, but the directional signal is clear: the final rule is a scaled-back version of the proposal.
New exemption pathway via Medicaid rebate agreement: A significant structural element not present in prior analysis has emerged. Endpoints News reporting based on internal CMS correspondence confirms that CMS has established an exemption from GLOBE (and the related GUARD program) for manufacturers who agree to provide additional rebates in Medicaid. This Medicaid-linked opt-out fundamentally alters the mandatory participation framing of the model. Manufacturers facing the largest GLOBE rebate exposure now have a negotiated exit ramp — but at the cost of expanded Medicaid rebate obligations. This creates a bifurcated manufacturer landscape: those who find the Medicaid rebate trade-off favorable will exit GLOBE; those who do not will remain subject to the international benchmark mechanism. CMS has essentially embedded a cross-program bargaining structure into what was framed as a mandatory model.
Modern Healthcare and Fierce Healthcare both characterize the final model as a "most favored nation" pricing approach applied to Part B — a framing that echoes the Trump first-term MFN model that was blocked by courts. This characterization is significant for litigation risk analysis (see below).
For manufacturers: The rebate obligation structure remains as described in the prior analysis. However, the Medicaid exemption pathway means the effective population of manufacturers subject to GLOBE rebates at model launch may be smaller than the proposed rule implied. Manufacturers who negotiate Medicaid rebate expansions will exit the GLOBE obligation, potentially concentrating the remaining rebate pool among manufacturers for whom Medicaid exposure is less strategically costly — likely smaller or single-product companies without large Medicaid books.
For providers and health systems: The financial mechanics remain intact — providers continue to receive ASP-based reimbursement and are not directly subject to the rebate obligation. The ASP erosion risk scenario (5–15% drift by 2029) remains a valid planning assumption, though the narrowed scope of the final rule means fewer drugs will be affected than the proposed rule suggested.
For beneficiaries: Coinsurance reductions remain the headline consumer benefit, though the aggregate beneficiary savings will be lower than the proposed rule projected, consistent with the narrowed scope confirmed in recent reporting.
The Medicaid exemption pathway introduces a new competitive dynamic not previously analyzed. Manufacturers who exit GLOBE via Medicaid rebate expansion will face different competitive pressures than those who remain in the model. For therapeutic classes where most major manufacturers negotiate Medicaid exits, the GLOBE benchmark mechanism may apply primarily to market entrants or manufacturers with limited Medicaid exposure — a potentially uneven competitive landscape within the same drug class.
Biosimilar manufacturers retain their indirect benefit: if reference biologic manufacturers remain in GLOBE (having declined the Medicaid exit), the benchmark compression improves biosimilar competitive positioning as previously described.
PhRMA has filed suit to block the GLOBE model. This is the single most consequential new development in the articles. Reporting from Endpoints News and Pharmaceutical Commerce confirms that PhRMA sued the Trump administration shortly after finalization, seeking to block the program. Pharmaceutical Commerce published detailed analysis of the legal theory underlying the challenge.
The litigation risk is material for several reasons:
MFN precedent: The Trump first-term Most Favored Nation model was blocked by federal courts on procedural and statutory grounds before implementation. GLOBE's functional similarity to MFN — as characterized by Modern Healthcare and Fierce Healthcare — means plaintiffs will likely invoke that precedent.
Section 1115A constraints: PhRMA's challenge will almost certainly argue that GLOBE exceeds CMMI's statutory authority, that mandatory manufacturer participation violates constitutional or APA constraints, or that the model does not meet the cost-neutrality requirements embedded in Section 1115A. The Medicaid exemption structure may itself become a litigation target if challengers argue it creates unlawful coercive conditions.
Implementation timeline risk: A preliminary injunction, if granted, could delay or suspend the January 1, 2027 launch. Health systems and manufacturers should treat the launch date as contingent on litigation outcomes, not assured. Planning should include a scenario in which GLOBE implementation is delayed 12–24 months or modified by court order.
The Wakely Week in Washington summary (October 8) references "several major legal developments this week could impact Medicare" in the context of Medicare lawsuits — consistent with the GLOBE litigation filing.
Physician perspective: No change from prior analysis. Oncologists, rheumatologists, and ophthalmologists administering GLOBE Model drugs will experience no change in their Part B payment mechanism. The operational burden remains on manufacturers and CMS.
Health system perspective: CFOs should add litigation scenario planning to the GLOBE drug inventory analysis previously recommended. The January 2027 launch is now subject to material legal uncertainty. Revenue accounting systems should be designed for a GLOBE implementation that may be delayed, modified, or enjoined.
Hospital perspective: The narrowed final rule scope reduces — but does not eliminate — the universe of drugs subject to GLOBE's coinsurance reduction mechanics. Outpatient infusion departments should update their drug-level scenario analyses to reflect the final rule's narrowed coverage before committing to staffing or capacity plans premised on volume increases from coinsurance reductions.
Payer/MA plan perspective: No change in direct applicability. Actuaries building 2028–2029 MA bids should continue to monitor GLOBE's indirect benchmark effects, but should now weight litigation-driven delay scenarios appropriately. If GLOBE implementation is enjoined through 2027 or 2028, the actuarial effect on Part B drug cost trends will be attenuated or absent in those years.
Manufacturer perspective: The strategic calculus has changed. The Medicaid rebate exemption pathway means manufacturers should immediately model the comparative financial exposure of (a) GLOBE rebate obligation versus (b) expanded Medicaid rebate commitment. That analysis, not a binary opt-in/opt-out decision, is now the primary strategic task. Manufacturers should also assess litigation exposure and consider whether participation in industry coalition litigation is consistent with their regulatory relationship strategy with the Trump administration.
GLOBE has moved from proposed rule to final rule — but the final rule is narrower and produces less savings than projected, PhRMA has filed suit to block it, and CMS has built in a Medicaid rebate exemption pathway that fundamentally complicates the mandatory participation framing. The model's January 2027 launch is now contingent on litigation outcomes. The data governance architecture concern raised in the prior analysis remains valid, but is now secondary to the litigation and exemption-pathway dynamics as the dominant strategic uncertainties. For health systems, the planning imperative shifts slightly: drug inventory analysis and ASP sensitivity modeling remain essential, but should now be paired with litigation scenario planning that treats the launch date as probabilistic rather than fixed. For manufacturers, the Medicaid exemption trade-off analysis is the immediate priority.
Published by ValuesEdge | Analysis updated to reflect October 2026 final rule reporting, PhRMA litigation filing, and Medicaid exemption pathway confirmation | Last source update: October 9, 2026